BioCentury
ARTICLE | Clinical News

GMI-1271: Phase I started

September 26, 2016 7:00 AM UTC

GlycoMimetics began an open-label, Irish Phase I trial to evaluate 4 dose levels of IV GMI-1271 plus Velcade bortezomib in about 24 patients who had an inadequate response to Velcade. ...